Exogenous melatonin for sleep problems in individuals with intellectual disability: a meta-analysis
| Autor: | Marcel G. Smits, Robert Didden, Hubert Korzilius, Wiebe Braam, Ingeborg M. van Geijlswijk, Leopold M. G. Curfs |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Male
Sleep Wake Disorders medicine.medical_specialty Developmental Disabilities Persons with Mental Disabilities Learning and Plasticity Exogenous melatonin Drug Administration Schedule law.invention Melatonin Developmental Neuroscience Randomized controlled trial law Tuberous Sclerosis Intellectual Disability Intellectual disability medicine Humans Relational Enterprise Child Randomized Controlled Trials as Topic business.industry Central Nervous System Depressants Melatonin treatment medicine.disease Sleep in non-human animals Child Development Disorders Pervasive Meta-analysis Pediatrics Perinatology and Child Health Physical therapy Female Neurology (clinical) Decreased sleep latency Angelman Syndrome business Sleep hormones hormone substitutes and hormone antagonists medicine.drug |
| Zdroj: | Developmental Medicine & Child Neurology, 51, 5, pp. 340-349 Developmental Medicine & Child Neurology, 51, 340-349 |
| ISSN: | 0012-1622 |
| Popis: | Contains fulltext : 77054.pdf (Publisher’s version ) (Closed access) Recent meta-analyses on melatonin has raised doubts as to whether melatonin is effective in treating sleep problems in people without intellectual disabilities. This is in contrast to results of several trials on melatonin in treating sleep problems in individuals with intellectual disabilities. To investigate the efficacy of melatonin in treating sleep problems in individuals with intellectual disabilities, we performed a meta-analysis of placebo-controlled randomized trials of melatonin in individuals with intellectual disabilities and sleep problems. Data were selected from articles published on PubMed, Medline, and Embase between January 1990 and July 2008. We examined the influence of melatonin on sleep latency, total sleep time, and number of wakes per night. Quality of trials was assessed using the Downs and Black checklist. Nine studies (including a total of 183 individuals with intellectual disabilities) showed that melatonin treatment decreased sleep latency by a mean of 34 minutes (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text